Sarcopenia in ElderlyNCT07080554
Observational and Analytical Study on the Diagnostic Criteria for Sarcopenia in Institutionalized Older Adults and Those Living in the Community
An observational study of Sarcopenia in Elderly and Institutionalized Older Adults, run by University of Extremadura at 1 site in Spain.
Trial summary
Sarcopenia is one of the main problems in the elderly population. However, its diagnostic criteria have not yet been studied in two specific populations, namely institutionalized older adults in nursing homes vs community-dwelling older adults. So this will be the objective of the study. Read more about this study
- Who is it for?
- Ages 60 years and olderHealthy volunteers can take part
- Conditions the study is for
- Sarcopenia in Elderly, Institutionalized Older Adults, Community-dwelling Elderly
- How many people
- 415 participants
- Where
- 1 siteSpain
- Study dates
- 1 Jan 2022to 1 Feb 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 60 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: The study will include two groups: one group of institutionalized older adults in nursing homes with clinical sospicius of sarcopenia and another group of community-dwelling older adults apparently healthy.
Who may be able to join
- older adults who have been institutionalized for at least one year
- older adults who are institutionalized with clinical suspicion of sarcopenia according to the Sarc-F questionnaire and muscle strength criteria
- older adults residing in the community of Extrema
Who cannot join
- present cognitive impairment (score <24 Mini-Mental State Examination)
- primary, serious, or chronic diseases that could explain the decrease in muscle strength and the other diagnostic variables of the participants
- diseases or physical disorders that hinder the assessment of the participants; -use of drugs that may affect muscle strength and mass [35].
Trial locations and contacts
1 site in 1 country.
About this study
Official title: "Analysis of Diagnostic Criteria for Primary Sarcopenia in Community-dwelling Older Adults vs. Institutionalized in Nursing Homes"
Sarcopenia is one of the main problems in the elderly population. However, its diagnostic criteria have not yet been studied in two specific populations, namely institutionalized older adults in nursing homes vs community-dwelling older adults. So this will be the objective of the study. An observational study is being conducted to analyze how these diagnostic criteria relate to each other and to find possible associations.
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| This group includes institutionalized older adults aged 60 and over. | Not described | |
| This group includes community-dwelling older adults aged 60 and over. | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Hand grip strenght
The researchers used the JAMAR dynamometer
Measured: Once at the baseline
Secondary outcomes (3)
Muscular mass / appendicular skeletal mass (ASM)
The researchers used bioimpedance analysis with Tanita MC780-S MA Multifrequency.
Measured: Once at the baseline
Physical performance
The researchers used the scale: "Short Physical Performance Battery" (SPPB),
Measured: Once at the baseline
Physical performance 2
The researchers used the test: "Timed Up and Go" (TUG)
Measured: Once at the baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Jul 2025
- Study start1 Jan 2022
- Primary completion1 Feb 2024
- Study completion1 Feb 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Sarcopenia in ElderlyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 415 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Extremadura
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Jesús Zapata Linares, University of Extremadura
- Investigators
- Luis Espejo-Antunez, Study director, University of Extremadura
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07080554
- Sponsor's protocol ID
- 01
- Status last verified
- Jul 2025
- First submitted
- 28 Jun 2025
- Last updated
- 8 Aug 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- "Analysis of Diagnostic Criteria for Primary Sarcopenia in Community-dwelling Older Adults vs. Institutionalized in Nursing Homes"
- ClinicalTrials.gov ID
- NCT07080554
- Acronym / sponsor ID
- 01
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 415 participants (actual)
- Lead sponsor
- University of ExtremaduraUniversity, hospital or other
- Study start
- 1 Jan 2022 (actual)
- Primary completion
- 1 Feb 2024 (actual)
- Study completion
- 1 Feb 2024 (actual)
- First posted
- 23 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Sarcopenia is one of the main problems in the elderly population. However, its diagnostic criteria have not yet been studied in two specific populations, namely institutionalized older adults in nursing homes vs community-dwelling older adults. So this will be the objective of the study. An observational study is being conducted to analyze how these diagnostic criteria relate to each other and to find possible associations.
Study design
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| This group includes institutionalized older adults aged 60 and over. | – | – |
| This group includes community-dwelling older adults aged 60 and over. | – | – |
Who may qualify
- Ages
- 60 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- The study will include two groups: one group of institutionalized older adults in nursing homes with clinical sospicius of sarcopenia and another group of community-dwelling older adults apparently healthy.
Key inclusion criteria (3 listed)
- older adults who have been institutionalized for at least one year
- older adults who are institutionalized with clinical suspicion of sarcopenia according to the Sarc-F questionnaire and muscle strength criteria
- older adults residing in the community of Extrema
Key exclusion criteria (3 listed)
- present cognitive impairment (score <24 Mini-Mental State Examination)
- primary, serious, or chronic diseases that could explain the decrease in muscle strength and the other diagnostic variables of the participants
- diseases or physical disorders that hinder the assessment of the participants; -use of drugs that may affect muscle strength and mass [35].
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Hand grip strenght
Time frame: Once at the baseline
The researchers used the JAMAR dynamometer
3 secondary outcomes
Muscular mass / appendicular skeletal mass (ASM)
Time frame: Once at the baseline
Physical performance
Time frame: Once at the baseline
Physical performance 2
Time frame: Once at the baseline
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Aug 2025.
Related trials for Sarcopenia in Elderly
Not yet recruiting
The Aim of the Study is to Decipher the Alterations in Signalling Pathways of Skeletal Muscle Stem Cells (Satellite Cells (SCs)) in Individuals With COPD, as Well as to Examine the Effect of Exercise Training on SCs.
COPD (Chronic Obstructive Pulmonary Disease), Sarcopenia in Elderly
Not yet recruitingPhase 2
MF-300 for Treatment of Age-Related Sarcopenia
Sarcopenia in Elderly
RecruitingObservational study
Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer
Colorectal Cancer, Sarcopenia
Not yet recruiting
Eccentric Exercise in Community-dwelling Older Adults
Ageing Well
Active, not recruitingPhase 2
TCM Formula vs. HMB in Pre-Frail Elders: Muscle Strength and Bone Status
Pre-Frailty, Sarcopenia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Luis Espejo-Antunez study director
University of Extremadura
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Sarcopenia in Elderly and Institutionalized Older Adults, run by University of Extremadura at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Hand grip strenght (time frame: Once at the baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Aug 2025.